Santen Pharmaceutical Co (SNPHY) AI Stock Analysis

• Market Cap: $3.72B
• Dividend Yield: 1.53%
• Average Volume (3M): 15.00
• Price to Earnings (P/E): 17.9
• Beta (1Y): 0.06
• Revenue Growth: -3.81%
• EPS Growth: 22.00%
• Country: US
• Employees: 3,744
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.12
• Shares Outstanding: 342,068,540
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 15
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 0.01
• Enterprise Value/Gross Profit: 0.02
• Enterprise Value/Ebitda: 0.05
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 77 Outperform
• Price Target: ―

Santen Pharmaceutical Co's strong financial performance is the primary driver of its stock score, reflecting consistent revenue growth and solid cash flow management. While the stock shows moderate bullish technical indicators, potential resistance at higher moving averages tempers the optimism. The valuation is fair, offering a reasonable investment proposition without significant under or overvaluation risks.

Santen Pharmaceutical Co Business Overview & Revenue Model

Company Description

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

How the Company Makes Money

Santen Pharmaceutical Co. generates revenue primarily through the sale of its ophthalmic products. The company's key revenue streams include prescription medications for conditions such as glaucoma, dry eye, and retinal disorders. In addition to prescription pharmaceuticals, Santen also earns revenue from over-the-counter products and medical devices designed to support eye health. The company actively invests in research and development to innovate and expand its product offerings, thereby enhancing its market position. Furthermore, Santen has established strategic partnerships and collaborations with other pharmaceutical companies and research institutions to co-develop and commercialize new treatments, which contribute to its revenue growth.

Santen Pharmaceutical Co Financial Statement Overview

Summary

Santen Pharmaceutical Co demonstrates strong financial health, characterized by consistent revenue growth, improving profitability margins, and solid cash flow management. The balance sheet reflects stability, although there is room for more efficient capital deployment. The company's financial trajectory is positive, with potential for continued growth and profitability.

Income Statement

Santen Pharmaceutical Co has shown robust revenue growth with a significant increase from the previous year, indicating strong market performance. Gross and net profit margins are healthy, reflecting efficient cost management and profitability. The recovery in EBIT and EBITDA margins from the previous year's negative EBIT further highlights operational improvements.

Balance Sheet

The company's balance sheet is strong, with a solid equity base and a favorable debt-to-equity ratio, indicating financial stability. The equity ratio is healthy, demonstrating a robust capital structure. However, the high amount of cash and equivalents suggests potential underutilization of resources.

Cash Flow

Cash flow performance is excellent, with substantial free cash flow growth and strong operating cash flow relative to net income. The company has effectively managed capital expenditures, enhancing its cash flow stability and flexibility.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	300.00B	300.00B	301.96B	279.04B	266.26B	249.60B
Gross Profit	171.23B	171.03B	178.71B	166.09B	156.59B	151.38B
EBITDA	67.23B	59.01B	50.72B	12.95B	52.93B	30.67B
Net Income	36.26B	36.26B	26.64B	-14.95B	27.22B	6.83B
Balance Sheet
Total Assets	409.28B	409.28B	435.70B	421.18B	459.98B	402.35B
Cash, Cash Equivalents and Short-Term Investments	93.99B	93.99B	94.96B	58.68B	84.31B	63.41B
Total Debt	0.00	0.00	35.16B	36.21B	32.93B	10.15B
Total Liabilities	124.10B	124.10B	130.33B	127.88B	123.13B	95.30B
Stockholders Equity	286.24B	286.24B	306.06B	293.98B	337.49B	307.58B
Cash Flow
Free Cash Flow	54.27B	54.27B	61.96B	12.56B	10.20B	15.00B
Operating Cash Flow	60.93B	60.93B	72.65B	37.15B	46.04B	38.81B
Investing Cash Flow	-8.22B	-8.22B	-6.14B	-26.78B	-35.17B	-53.35B
Financing Cash Flow	-53.31B	-53.31B	-34.03B	-37.22B	5.56B	-16.68B

Santen Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.96
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNPHY, the sentiment is Negative. The current price of 10.96 is below the 20-day moving average (MA) of 11.02, above the 50-day MA of 10.95, and above the 200-day MA of 10.41, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 48.63 is Neutral, neither overbought nor oversold. The STOCH value of 20.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNPHY.

Santen Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SNPHY	77 Outperform	$3.72B	17.92	10.89%	1.53%	-3.81%	22.00%
BIIB	73 Outperform	20.18B	12.98	9.76%	―	3.48%	31.44%
GRFS	61 Neutral	8.56B	20.56	2.67%	1.46%	10.05%	98.22%
OGN	55 Neutral	2.71B	3.87	95.50%	5.93%	-1.02%	-30.57%
CTOR	47 Neutral	151.16M	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%